Mexico City /
the chinese lab Cansino Biologics announced that it will request authorization from the Mexican health authorities to carry out its phase 3 clinical trial in the country for the inhaled version of the vaccine against covid-19.
“We are gathering the necessary documentation to request authorization for phase 3 of the clinical trial of the inhaled version of the Cansino vaccine against covid-19. We will be reporting the process by this means,” he reported via Twitter.
We are gathering the necessary documentation to request authorization for phase 3 of the clinical trial of the inhaled version of the #CansinoVaccine against Covid-19. We will be reporting the process by this means. #TiredInMexico
— Cansino Biologics Mexico (@CansinoBio) March 19, 2022
–
The laboratory highlighted that the nasal spray vaccine developed by its CansinoBio team requires only a fifth of the dose compared to the injectable vaccine.
“We are pleased to inform you that we continue to work hard so that we will soon be able to offer our inhaled vaccine against Covid-19, which provides more complete protection,” he added.
In June 2021, Cansino’s inhalable vaccine was authorized for emergency use in China, as an alternative for healthy people aged 2 to 49 who are not pregnant and wish to protect themselves from the virus; so now they seek approval in Mexico.
“The inhaled version of the Cansino vaccine against covid-19 stimulates mucosal and humoral immunity, which represents an extra layer of protection,” the laboratory said.
This vaccine takes approximately two weeks to develop antibodies after its application.
RLO
–
–
